A Review on Cipla Liposomes (Dsoxorubicin and Amphotericin B)

Abstract

The Cipla has developed strategies in technologies such as sustained release and combination products, and also in made better improvements to enhance drug delivery system capabilities. Liposomal technology is new technique used by us to improve the delivery of drugs. These delivery system gives opportunity to target drugs on their respective sites may improve the pharmacological effect and also pharmacokinetics of the drug. Cipla has introduced the new liposomal formulations for anticancer drug (Doxorubicin) and anti-fungal drug (Amphotericin-B). Doxorubicin is an anticancer drug and it is a chemotherapy medication. Cipla laboratories had introduced these liposomal doxorubicin drugs for targeting tumours. Doxorubicin is in pegylated form reduces cytotoxicity and improve the efficacy of the drug. Conventional Amphotericin drugs causes cytotoxicity, reduce the efficacy these liposomes formulation may improve the efficacy of the drug and acts as anti-fungal drug. Phosome Amphotericin B is a polyene antifungal which alters cell membrane permeability by binding and forms the suspectable fungal membrane.